03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Non-medicated preparations for body and beauty care. Medicinal preparations; pharmaceuticals; medicated nasal
spray preparations; biochemical preparations for medical
use; non-medical nasal sprays.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and medical preparations, namely medicated
nasal spray preparations, medicated throat sprays, medicated
mouth sprays, medicated sprays for wound care, medicated
skin sprays, medicated lotions and creams for wound and skin
care, medicated ear sprays and throat lozenges.
3.
CARBOXYLIC ACIDS FOR TREATING/PREVENTING A SKIN DISEASE
The present invention relates to a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof as active ingredient for use in treating and/or preventing a skin disease. The invention also relates to a method for treating and/or preventing a skin disease of a patient, the method comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof. Furthermore, the invention provides cosmetic uses of a composition comprising a carboxylic acid or a salt thereof for reducing redness of the skin, skin lesions, wrinkles, impurities or irregularities of the skin. In addition, the present invention relates to a pharmaceutical composition comprising as active ingredient a carboxylic acid or a pharmaceutically acceptable salt thereof for use in improving barrier function of the skin, wherein the pharmaceutical composition is administered to an infant and a method for treating and/or preventing a skin disease of a patient, the method comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof.
The present invention relates to a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof as active ingredient for use in treating and/or alleviating and/or preventing nasal congestion, a viral infectious disease of the respiratory tract or an inflammation of the throat. Furthermore, the present invention relates to a method for treating and/or alleviating and/or preventing nasal congestion, viral infections of the respiratory tract and/or inflammation of the throat in. a patient, comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof. In addition, the present invention relates to a method for alleviating the symptoms associated with nasal congestion, viral infections of the respiratory tract and/or inflammation of the throat comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof.
The present invention relates to a pharmaceutical composition comprising as active ingredient a carboxylic acid or a pharmaceutically acceptable salt thereof for use in improving barrier function of the skin, wherein the pharmaceutical composition is administered to an infant. The invention also relates to a method for treating and/or preventing a skin disease of a patient, the method comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof.
The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/25 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
7.
Esters of short chains fatty acids for use in the treatment of immunogenic disorders
The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/25 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
8.
ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS
The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/25 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/25 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The present invention relates to short chain fatty acids (SCFA) for modulating a Th2 immune response towards a Th1 immune response for prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders, particularly of a disease or disorder mediated by T helper 2 (Th2) cell-derived cytokines, including, without being limited to, !L-4. IL-5, IL-6, IL-8, IL-10 and IL-13, but particularly for use in the treatment of IL-4 and/or IL-8 and/or IgE mediated diseases or disorders and/or eosinophilic diseases or disorders.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
